SETD2 and cancer: SETD2‐mutant cancers have showed a substantial decrease in global H3K36me3 levels.47 Additionally, the loss of function of SETD2 has been shown to sensitize tumors to PI3KB inhibitors48 and is under investigation as a target for other agents in phase I and II clinical trials, making it a novel potential therapeutic target in this disease.